Jennifer Jarrett Sells 11,225 Shares of Arcus Biosciences (NYSE:RCUS) Stock

20 Dec 2025, 05:18 by Renee Jackson · The Cerbat Gem

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) COO Jennifer Jarrett sold 11,225 shares of Arcus Biosciences stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the sale, the chief operating officer directly owned 203,007 shares of the company’s stock, valued at $4,441,793.16. This represents a 5.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jennifer Jarrett also recently made the following trade(s):

On Wednesday, December 17th, Jennifer Jarrett sold 9,983 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total transaction of $221,223.28.
On Monday, October 6th, Jennifer Jarrett sold 12,500 shares of Arcus Biosciences stock. The stock was sold at an average price of $14.54, for a total transaction of $181,750.00.
On Wednesday, October 8th, Jennifer Jarrett sold 37,792 shares of Arcus Biosciences stock. The shares were sold at an average price of $15.05, for a total transaction of $568,769.60.

Arcus Biosciences Stock Performance

Shares of NYSE:RCUS opened at $21.99 on Friday. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $26.40. The company’s 50 day moving average price is $21.10 and its two-hundred day moving average price is $14.13. The firm has a market cap of $2.37 billion, a PE ratio of -6.39 and a beta of 0.75. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. During the same period in the previous year, the company posted ($1.00) earnings per share. The firm’s revenue for the quarter was down 45.8% compared to the same quarter last year. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

RCUS has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price target on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Finally, Bank of America upped their target price on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.89.

View Our Latest Research Report on RCUS

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently added to or reduced their stakes in RCUS. Goldman Sachs Group Inc. increased its stake in shares of Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after buying an additional 470,755 shares during the period. Geode Capital Management LLC grew its holdings in Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock worth $12,995,000 after acquiring an additional 207,097 shares during the last quarter. Rhumbline Advisers grew its holdings in Arcus Biosciences by 14.8% during the 1st quarter. Rhumbline Advisers now owns 182,909 shares of the company’s stock worth $1,436,000 after acquiring an additional 23,645 shares during the last quarter. Tema Etfs LLC increased its position in Arcus Biosciences by 291.2% in the 2nd quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock valued at $486,000 after acquiring an additional 44,411 shares during the period. Finally, Woodline Partners LP raised its stake in shares of Arcus Biosciences by 45.5% during the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after acquiring an additional 1,603,367 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.